• Media type: E-Article
  • Title: Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year
  • Contributor: Fleischhacker, W. Wolfgang; Rabinowitz, Jonathan; Kemmler, Georg; Eerdekens, Mariëlle; Mehnert, Angelika
  • Published: Royal College of Psychiatrists, 2005
  • Published in: British Journal of Psychiatry, 187 (2005) 2, Seite 131-136
  • Language: English
  • DOI: 10.1192/bjp.187.2.131
  • ISSN: 0007-1250; 1472-1465
  • Origination:
  • Footnote:
  • Description: BackgroundThe extent to which antipsychotics improve patients' well-being is uncertain.AimsTo examine psychopathology and patient-rated functioning and well-being in patients treated with risperidone.MethodIn a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF–36). Psychopathology was quantified using the Positive and Negative Syndrome Scale (PANSS).ResultsSignificant improvements were found on the SF–36 mental component summary score and vitality and social functioning scales. PANSS and mental component summary scores were moderately correlated.ConclusionsPatient-reported functioning and well-being appear to differ from investigator-rated psychotic symptoms. Patient-rated well-being should be assessed with symptoms to help measure treatment outcomes.
  • Access State: Open Access